so few patients. what was the follow-up period. will be interesting to see if the drug can have a sustained effect on the tumor, or if it (the tumor) simply develops resistance a few months latter and not affect overall survival to any significant extent. Previous phase III study with Vintafolide extended progression free survival by only 2.3 months. In 2014 Merck and Endocyte stopped a late-stage study of vintafolide in treating ovarian cancer on the recommendation of a data safety monitoring board, saying that the drug failed to improve progression-free survival. To me, it seems like the bump in stock price was too much considering that the company's previous attempt to bring a drug conjugate to market failed (IMGN901) and the failure of Kadcyla. IMO
Latest Comments
ImmunoGen Reports Positive Results In Patients With Platinum-Resistant Ovarian Cancer
so few patients. what was the follow-up period. will be interesting to see if the drug can have a sustained effect on the tumor, or if it (the tumor) simply develops resistance a few months latter and not affect overall survival to any significant extent. Previous phase III study with Vintafolide extended progression free survival by only 2.3 months. In 2014 Merck and Endocyte stopped a late-stage study of vintafolide in treating ovarian cancer on the recommendation of a data safety monitoring board, saying that the drug failed to improve progression-free survival. To me, it seems like the bump in stock price was too much considering that the company's previous attempt to bring a drug conjugate to market failed (IMGN901) and the failure of Kadcyla. IMO